MHRAgovuk· @MHRAgovuk · X·· 2026-07-31精选AI 评分62
AI 导读
MHRA宣布本周与NICE同步批准aficamten，用于梗阻性肥厚型心肌病患者。MHRA称这一决定体现了卫生系统内更紧密协作可让患者更快获得创新疗法，同时不牺牲安全性。
推荐理由
原文给出MHRA与NICE同步批准aficamten用于梗阻性肥厚型心肌病，读者可了解英国监管与卫生评估协同加速准入的做法。
正文
🔁Faster access to treatments, without compromising safety.
Our approval of aficamten this week, alongside NICE, marks an important milestone for patients with obstructive hypertrophic cardiomyopathy, made possible through strengthened collaboration across the health system.
@MHRAgovuk said the decision highlights how closer collaboration can help patients access innovative treatments sooner.在 X 查看被引用的帖子
来源：MHRAgovuk · x.com